

SUPPLEMENTAL MATERIAL

Supplemental Table 1. Characteristics of SPS3 Participants by eGFR (in ml/min/1.73m²) level at baseline

Characteristic	Overall	eGFR >90	eGFR 60-90	eGFR <60
N	2610	867	1331	410
Age	63.4 (10.7)	58.0 (8.2)	65.0 (10.4)	69.9 (10.9)
Male Gender	1655 (63%)	570 (66%)	849 (64%)	236 (58%)
Race				
Non-Hispanic				
White	1298 (50%)	377 (43%)	704 (53%)	217 (53%)
Black	384 (15%)	149 (17%)	181 (14%)	54 (13%)
Hispanic	854 (33%)	325 (37%)	405 (30%)	124 (30%)
Other/mixed	75 (3%)	17 (2%)	43 (3%)	15 (4%)
Region				
North America	1674 (64%)	546 (63%)	872 (65%)	256 (62%)
Latin America	647 (25%)	217 (25%)	326 (25%)	104 (25%)
Spain	290 (11%)	105 (12%)	135 (10%)	50 (12%)
Smoking				
Never	1035 (40%)	322 (37%)	539 (40%)	174 (42%)
Current	507 (19%)	240 (28%)	216 (16%)	51 (12%)
Past	1069 (41%)	306 (35%)	578 (43%)	185 (45%)
BMI	29.1 (7.0)	29.7 (8.7)	28.9 (5.9)	28.6 (5.8)
Diabetes	949 (36%)	371 (43%)	423 (32%)	155 (38%)
Baseline HTN	2339 (90%)	744 (86%)	1207 (91%)	388 (95%)
ARB Use	428 (16%)	102 (12%)	242 (18%)	84 (20%)

(baseline)				
ACE Use				
(baseline)	1375 (53%)	471 (54%)	693 (52%)	211 (51%)
CCB (baseline)	665 (26%)	161 (19%)	368 (28%)	136 (33%)
BB (baseline)	641 (25%)	169 (19%)	332 (25%)	140 (34%)
Diuretic (baseline)	951 (36%)	271 (31%)	492 (37%)	188 (46%)
Other (baseline)	177 (7%)	42 (5%)	90 (7%)	45 (11%)
ARB (year 1)	704 (27%)	210 (25%)	352 (27%)	142 (35%)
ACE (year 1)	1201 (47%)	411 (48%)	624 (48%)	166 (41%)
CCB (year 1)	938 (37%)	253 (30%)	503 (38%)	182 (45%)
BB (year 1)	716 (28%)	193 (23%)	381 (29%)	142 (35%)
Diuretic (year 1)	1488 (58%)	458 (54%)	776 (59%)	254 (63%)
Other (year 1)	252 (10%)	52 (6%)	131 (10%)	69 (17%)
History of TIA	146 (6%)	50 (6%)	63 (5%)	33 (8%)
SBP (mmHg)				
Baseline	143 (19)	140 (17)	143 (19)	146 (20)
3 month	133 (16)	132 (15)	134 (16)	136 (17)
9 month	132 (15)	131 (14)	132 (15)	133 (15)
eGFR				
ml/min/1.73m ²	80 (18.5)	100 (7.7)	76 (8.4)	51 (7.1)

BMI=body mass index, ACE= angiotensin converting enzyme inhibitor, ARB= angiotensin receptor blocker, CCB= calcium channel blocker, BB= beta blocker, TIA= history of transient ischemic attack, SBP=systolic blood pressure

2 persons are missing creatinine data at baseline, but have at least two values at follow-up (are included in overall)

Supplemental Table 2. The Association of Selected Characteristics, Achieved SBP and Baseline Use of Anti-Hypertensive Medication Classes with Rapid Kidney Function Decline Among SPS3 Participants (n=2520)

Characteristic	Adjusted* OR (95%CI)
Age (per 11 years)	1.2 (1.0, 1.3)
Achieved SBP (per SD increase)	1.2 (1.1, 1.3)
ACE or ARB	1.3 (1.0, 1.7)
ACE and ARB	1.1 (0.4, 2.8)
Diuretic	1.1 (0.9, 1.4)
CCB	1.2 (1.0, 1.6)
Beta Blocker	1.6 (1.2, 2.0)
Diabetes	2.1 (1.7, 2.6)
Current Smoking (vs. never)	1.4 (1.0, 1.9)
eGFR (ml/min/1.73m ²)	1.1 (0.9, 1.2)

*Adjusted for treatment arm (in overall), age, gender, race/ethnicity, smoking, diabetes, history of TIA, region, BMI, baseline use of ACE, ARB, diuretic, calcium channel blocker, beta blocker (each adjusted for use of the other classes), baseline eGFR. ACE or ARB= use of one (vs. none), ACE and ARB means use of both (vs. none)

Supplemental Figure 1. The Effect of Usual vs. Intensive BP Lowering and Kidney Function Decline by Age, Diabetes and Chronic Kidney Disease Status at Baseline




Figure Legend: Estimates represent eGFR in ml/min/1.73m² per year from the linear mixed model